Tilahun Mihret, Belete Melaku Ashagrie, Gedefie Alemu, Debash Habtu, Alemayehu Ermiyas, Weldehana Daniel Gebretsadik, Ebrahim Hussein, Mohammed Ousman, Eshetu Bruktawit, Tekele Saba Gebremichael, Mulatie Zewudu, Shibabaw Agumas
Department of Medical Laboratory Sciences, College of Medicine and Health Sciences, Wollo University, Dessie, P.O. Box: 1145, Ethiopia.
BMC Infect Dis. 2025 Jan 10;25(1):52. doi: 10.1186/s12879-024-10425-w.
Salmonella and Shigella are major enteric pathogens that cause diarrhea in children worldwide. They are pathogenic microbes that cause significant diarrheal morbidity and mortality in under five children in resource limited countries. Thus, this systemic review and meta-analysis aimed to investigate the prevalence of Salmonella and Shigella species and their multidrug resistance patterns in pediatric populations in Ethiopia.
The articles were searched extensively in the electronic databases and grey literature using entry terms or phrases. Studies meeting the eligibility criteria were extracted in MS Excel and exported for statistical analysis into STATA version 14 software. The overall pooled prevalence of Salmonella and Shigella species was computed using a random-effects model. Heterogeneity was assessed using the Cochrane Q test and I statistics with corresponding p-values. Publication bias was assessed using a funnel plot and Egger's test. In addition, sensitivity analysis was performed to determine the impact of individual studies on the pooled effect size.
Of a total of 742 identified studies, 89 studies were eligible for full-text analysis. Of 89 studies, 21 were included for meta-analysis involving 5318 study participants. These eligible studies reported a total of 593 bacterial isolates. The overall pooled prevalence of Salmonella and Shigella among pediatrics in Ethiopia was 10.70% (95% CI: 8.96-12.45), with substantial heterogeneity (I = 82.1%, p < 0.001) across the studies. The pooled prevalence of Salmonella and Shigella individually among pediatrics in Ethiopia was 15.43% (95% CI: 10.42-20.72) and 15.83% (95% CI: 11.40-20.40), respectively. Moreover, the overall prevalence of multidrug resistance in Salmonella and Shigella isolates was 81.03% (95% CI: 77.39-84.67) with substantial heterogeneity of I of 95%, p < 0.0001 between the pooled prevalence of the two species.
The pooled prevalence of Salmonella and Shigella and their multidrug resistance were alarmingly high in pediatric. The initial empirical treatment of pediatrics patients remains challenging and results high prevalence of antimicrobial resistance. Thus, appropriate infection prevention and control strategies should be implemented and treatment should be directed based on antimicrobial stewardship protocols.
沙门氏菌和志贺氏菌是导致全球儿童腹泻的主要肠道病原体。在资源有限的国家,它们是导致五岁以下儿童腹泻发病率和死亡率显著升高的致病微生物。因此,本系统评价和荟萃分析旨在调查埃塞俄比亚儿科人群中沙门氏菌和志贺氏菌的流行情况及其多重耐药模式。
使用检索词或短语在电子数据库和灰色文献中广泛检索文章。将符合纳入标准的研究录入MS Excel,并导出至STATA 14软件进行统计分析。采用随机效应模型计算沙门氏菌和志贺氏菌的总体合并患病率。使用Cochrane Q检验和I统计量及相应的p值评估异质性。使用漏斗图和Egger检验评估发表偏倚。此外,进行敏感性分析以确定个别研究对合并效应量的影响。
在总共742项已识别的研究中,89项研究符合全文分析的条件。在这89项研究中,21项被纳入荟萃分析,涉及5318名研究参与者。这些符合条件的研究共报告了593株细菌分离株。埃塞俄比亚儿科人群中沙门氏菌和志贺氏菌的总体合并患病率为10.70%(95%置信区间:8.96 - 12.45),各研究间存在显著异质性(I = 82.1%,p < 0.001)。埃塞俄比亚儿科人群中沙门氏菌和志贺氏菌各自的合并患病率分别为15.43%(95%置信区间:10.42 - 20.72)和15.83%(95%置信区间:11.40 - 20.40)。此外,沙门氏菌和志贺氏菌分离株的总体多重耐药率为81.03%(95%置信区间:77.39 - 84.67),两种菌合并患病率之间的异质性高达95%,p < 0.0001。
沙门氏菌和志贺氏菌在儿科人群中的合并患病率及其多重耐药率高得惊人。儿科患者的初始经验性治疗仍然具有挑战性,且抗菌药物耐药率很高。因此,应实施适当的感染预防和控制策略,并根据抗菌药物管理方案进行治疗指导。